Nevro is a medical devices business based in the US. Nevro shares (NVRO) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $5.84 – the same closing value as a week prior. Nevro employs 1,099 staff and has a trailing 12-month revenue of around $408.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.84 |
|---|---|
| 52-week range | $3.17 - $11.69 |
| 50-day moving average | $5.63 |
| 200-day moving average | $5.64 |
| Wall St. target price | $7.07 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.06 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.84 from 2025-04-02
| 1 week (2025-04-26) | N/A |
|---|---|
| 1 month (2025-04-03) | N/A |
| 3 months (2025-02-07) | 2.10% |
| 6 months (2024-11-07) | 9.36% |
| 1 year (2024-05-07) | -49.35% |
|---|---|
| 2 years (2023-05-05) | -78.43% |
| 3 years (2022-05-06) | 50.91 |
| 5 years (2020-05-06) | 119.11 |
| Revenue TTM | $408.5 million |
|---|---|
| Gross profit TTM | $269.5 million |
| Return on assets TTM | -9.95% |
| Return on equity TTM | -43.29% |
| Profit margin | -27.77% |
| Book value | $6.11 |
| Market Capitalization | $224.1 million |
TTM: trailing 12 months
We're not expecting Nevro to pay a dividend over the next 12 months.
Nevro's shares were split on a 1:24 basis on 5 November 2014 . So if you had owned 24 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nevro shares – just the quantity. However, indirectly, the new 2300% higher share price could have impacted the market appetite for Nevro shares which in turn could have impacted Nevro's share price.
Over the last 12 months, Nevro's shares have ranged in value from as little as $3.165 up to $11.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Nevro's is 0.817. This would suggest that Nevro's shares are less volatile than average (for this exchange).
Nevro Corp. , a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.